Nebivolol    (DrugBank: Nebivolol)

3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
17多系統萎縮症1
113筋ジストロフィー2
167マルファン症候群2

17. 多系統萎縮症 [臨床試験数:107,薬物数:153(DrugBank:48),標的遺伝子数:59,標的パスウェイ数:104
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 107 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01044693
(ClinicalTrials.gov)
January 20106/1/2010Nebivolol in the Supine Hypertension of Autonomic FailureEffect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide BioactivityHypertension;Pure Autonomic Failure;Multiple System AtrophyDrug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mgVanderbilt UniversityForest LaboratoriesCompleted18 Years80 YearsAll20N/AUnited States

113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 567 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01648634
(ClinicalTrials.gov)
February 13, 201220/7/2012Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyA Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyDuchenne Muscular Dystrophy;Cardiomyopathy;Heart FailureDrug: Nebivolol;Drug: PlaceboAssistance Publique - Hôpitaux de ParisAssociation Française contre les Myopathies (AFM), ParisActive, not recruiting10 Years15 YearsMale51Phase 3France
2EUCTR2010-020047-12-FR
(EUCTR)
01/04/2011Effet d’un traitement préventif par Nebivolol chez les enfants atteints de dystrophie de DuchenneEtude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne - NEBIDYS Enfants atteints de dystrophie de Duchenne
MedDRA version: 13.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Temerit
Product Name: Temerit
INN or Proposed INN: Nébivolol
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNAFemale: no
Male: yes
Phase 3France

167. マルファン症候群 [臨床試験数:19,薬物数:38(DrugBank:10),標的遺伝子数:10,標的パスウェイ数:49
Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-001462-81-IT
(EUCTR)
27/10/200817/03/2008Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDEffects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND Marfan Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: LORTAAN*28CPR RIV DIV 50MG
INN or Proposed INN: Losartan
Trade Name: LOBIVON*28CPR 5MG
INN or Proposed INN: Nebivolol
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
Phase 3Italy
2NCT00683124
(ClinicalTrials.gov)
July 200821/5/2008Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan PatientsEffects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.Marfan SyndromeDrug: Losartan and nebivolol;Drug: Losartan;Drug: NebivololIRCCS Policlinico S. MatteoMerck Sharp & Dohme Corp.;Menarini GroupRecruiting12 Months55 YearsBoth291Phase 3Italy